• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT shares dip despite street-beating Q4 earnings

February 26, 2019 By Fink Densford

Intersect ENT updated

Shares in Intersect ENT (NSDQ:XENT) have fallen slightly today despite the medical device maker releasing fourth quarter and full year 2018 earnings that met consensus expectations from analysts on Wall Street.

The Menlo Park, Calif.-based company posted losses of $5 million, or 16¢ per share, on sales of approximately $32.8 million for the three months ended December 31, seeing losses grow 59.6% while sales grew 11% compared with the same period during the previous year.

Intersect ENT’s loss-per-share numbers were just in line with the 16¢ consensus on Wall Street, where analysts expected to see sales of $32.5 million, which the company topped.

For the full year, Intersect ENT posted losses of $22.9 million, or 76¢ per share, on sales of $108.5 million, seeing losses grow 40.1% while sales grew 12.6% compared with the previous fiscal years.

The company was just ahead of the 75¢ loss-per-share expectations on Wall Street, where analysts expected to see sales of $108 million, which the company also topped.

Intersect ENT released guidance for the 2019 year, expecting to post sales of between $123 million and $127 million, with first quarter sales of between $26 million and $26.5 million, according to a press release.

Shares in Intersect ENT have fallen 2.6% today, at $33.65 as of 12:57 p.m. EST.

Last December, Intersect ENT said that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS